DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven ...
Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...
Today, prominent investor rights law firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G") filed a class action in the U.S. District Court for the Southern District of New York alleging violations ...
Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, expectations were $0.57. Operator: Ladies and gentlemen, welcome to the DexCom Third ...
For the quarter ended September 2025, DexCom (DXCM) reported revenue of $1.21 billion, up 21.6% over the same period last year. EPS came in at $0.61, compared to $0.45 in the year-ago quarter. The ...
Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” third-quarter 2025 investor ...
StockStory.org on MSN
The 5 Most Interesting Analyst Questions From DexCom’s Q3 Earnings Call
DexCom's third quarter was met with a negative market reaction despite outpacing Wall Street’s revenue and adjusted EPS ...
DexCom (DXCM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook gives a ...
DexCom, a leading manufacturer of continuous glucose monitoring systems, is confronting one of the most significant challenges in its corporate history. Regu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback